Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in X-linked Alport Syndrome
NCT04937907Phase 2Completed
- Sponsor
- Shanghai Children's Hospital
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxychloroquine in X-linked Alport syndrome (XLAS) (2 cohorts), sponsored by Shanghai Children's Hospital. Primary endpoint: Change in urinary erythrocyte count per high-power field at 48 weeks. Started Sep 2021; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
X-linked Alport syndrome (XLAS)
Beyond the preview
Go deeper on NCT04937907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937907.